Focus on HIV Care

Back to articles

New Drugs, Regimens Presented at Infectious Disease Meeting

KEY POINT

New choices for treating HIV infection and AIDS include atazanavir (Bristol-Myers Squibb) and the fusion inhibitors, according to presenters at last month’s Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC; www.icaac.org). In addition, rechallenge may be worthwhile and safe in patients who have had hyperlactatemia during treatment with nucleoside reverse transcriptase inhibitors (NRTIs), and once-daily dosing may be feasible with lamivudine (Epivir—GlaxoSmithKline).

SOURCES

Squires KE et al. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (A1424-034). Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 28, 2002.

Agarwala S. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 29, 2002.

O’Mara E et al. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate–glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy sub- jects. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 29, 2002.

Lalezari JPet al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (ARV) resistance. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 28, 2002.

Gulick R. Complete analysis of T1249-101: safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of HIV membrane fusion. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 28, 2002.

Lonergan T et al. Long-term safety and efficacy of rechallenging patients who have recovered from serious symptomatic hyperlactatemia with new NRTI-containing regimens. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 28, 2002.

Dejesus E et al. Comparable antiviral efficacy and safety of lamivudine administered 300 mg once daily (QD) versus 150 mg BID both in combination with zidovudine (300 mg BID) and efavirenz (600 mg QD) in HIV-1 infected, antiretroviral-naìˆve adults: EPV20001. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemother- apy, San Diego, Calif., September 27, 2002.